Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction of HPV Viral Infectivity and Transmission in HPV16/18-Positive Women After Vaccination With 9vHPV
NCT05334706Phase 4Recruiting
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection. Primary endpoints: Change in viral infectivity in cervical, anal and oral samples at 7 months, Detection of HPV 6/11/16/18/31/33/45/52/58 L1 antibodies at 7 months and 3 more. Started Sep 2022; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05334706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334706.